How to make your money go further

Astra vs GSK. Drugs vs Dividends.

16/11/2018 · AstraZeneca (AZN)  · GlaxoSmithKline (GSK) 

Dividends FTSE 100 Shares

Update: AstraZeneca has failed another drugs trial. That's the risk of its strategy which has been to focus on bulking up its pipeline with exciting, novel therapies. It's very different to the 'steady as she goes' approach employed by GlaxoSmithKline which, though underwhelming, might be better for income seekers.

Sign up and read the full article

Register to continue reading this article.

Get FREE access now

Already a member? Login

Have your say

Log in or register to view or add comments.

Get free access now

Register free to gain access to more research

Register

Investor's Champion Premium Content

Subscribers to our Premium Content receive priority notification by email of newly published research. Premium Content costs as little as £3.20 per research note.

More on Premium Content

More on AstraZeneca

Astra vs GSK. Drugs vs Dividends.

16/11/2018 · Blog
Update: AstraZeneca has failed another drugs trial. That's the risk of its strategy which has been…

More on GlaxoSmithKline

New Year, new you: profit from your resolutions

07/01/2019 · Portfolio
This January, thousands of us will drag ourselves into the gym, or spend our days craving…

GlaxoSmithKline split: a winning strategy?

19/12/2018 · Get Investing
Shareholders seem to like the GSK split proposal, with the price up strongly off the back…

Astra vs GSK. Drugs vs Dividends.

16/11/2018 · Blog
Update: AstraZeneca has failed another drugs trial. That's the risk of its strategy which has been…

More from the Blog

Patisserie Holdings - it’s even worse than thought, what next?

16/01/2019 · Patisserie Holdings PLC

Bargain hunting: 1pm looks ridiculously cheap

16/01/2019 · 1PM PLC

Creo Medical and Get Busy are AIMing high